Table 3.
Univariate analysis based on EMD site and time of EMD onset
| EMD site | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any CNS | Skin only | Lymph node only | Other | No EMD | |||||||
| Outcomes | N | Prob | N | Prob | N | Prob | N | Prob | N | Prob | P-value |
| Overall survival | 283 | 155 | 112 | 264 | 8983 | ||||||
| 1-year | 55 (49–60)% | 44 (36–52)% | 60 (50–69)% | 54 (48–60)% | 54 (53–55)% | 0.11 | |||||
| 3-year | 42 (36–48)% | 35 (27–42)% | 43 (33–52)% | 41 (35–47)% | 40 (39–41)% | 0.62 | |||||
| 5-year | 39 (33–45)% | 28 (21–36)% | 34 (25–44)% | 37 (31–44)% | 35 (34–37)% | 0.28 | |||||
| Time of EMD onset | |||||||
|---|---|---|---|---|---|---|---|
| At diagnosis | At transplant | No EMD | |||||
| Outcomes | N Eval | Prob (95% CI) | N Eval | Prob (95% CI) | N Eval | Prob (95% CI) | P-value |
| Overall survival | 602 | 159 | 8983 | ||||
| 1-year | 55 (51–59)% | 45 (37–53)% | 54 (53–55)% | 0.07 | |||
| 3-year | 42 (38–46)% | 34 (26–41)% | 40 (39–41)% | 0.15 | |||
| 5-year | 37 (33–41)% | 30 (22–37)% | 35 (34–37)% | 0.27 | |||